-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 4, the Yunnan Provincial Food and Drug Administration announced that Kunming Xuanqing Biotechnology Co.
, Ltd.
applied for the cancellation of the "Drug Production License" (No.
: Yunnan 20160153) to terminate the production of drugs
.
The cancellation of the application complies with the "Drug Administration Law of the People's Republic of China" (Order No.
31 of the President of the People's Republic of China) and other laws and regulations, and has been studied by the Yunnan Provincial Drug Administration and agreed to be cancelled
.
In fact, under the background of stricter industry supervision and fierce market competition, pharmaceutical companies that do not operate in a standardized way and are unable to operate are constantly withdrawing from the market in recent years
.
At present, judging from the fact that the provincial drug administrations have started to expose the inspection results of pharmaceutical companies in 2021, this trend is still accelerating.
In 2019, more than 10 pharmaceutical companies have been ordered to suspend production due to their own reasons or found illegal projects during the inspection of the Food and Drug Administration
.
For example, on December 31, the Hunan Provincial Food and Drug Administration issued an announcement stating that, according to the application of Huaihua Longyuan Pharmaceutical Co.
, Ltd.
Ethnic Chinese Herbal Pieces Factory and Zhijiang Dong Autonomous County Herbal Medicine Company Chinese Herbal Pieces Factory, the provincial bureau cancelled Huaihua Longyuan according to law.
The "Drug Production License" (No.
: Xiang 20160163), "Drug GMP Certificate" (Certificate No.
: HN20160194) of the Nationality Traditional Chinese Medicine Decoction Piece Factory of the Pharmaceutical Co.
, Ltd.
and the "Drug Production License" ( No.
: Xiang 20170207), "Drug GMP Certificate" (Certificate No.
: HN20170260)
.
On the same day, according to a production suspension notice issued by the Anhui Provincial Food and Drug Administration, Anhui Jucao Chinese Herbal Pieces Co.
, Ltd.
was found to have 1 serious defect (the drug quality management system could not operate effectively), and the Chinese medicine pieces had potential quality and safety hazards.
He was ordered by the Food and Drug Administration to suspend the production of Chinese herbal decoction pieces and filed a case for investigation
.
In addition, the Guangxi Zhuang Autonomous Region Food and Drug Administration also issued a notice on December 31 on the results of the special inspection on pharmacovigilance of drug manufacturers in 2021
.
The notice shows that a total of 39 pharmaceutical companies have been inspected this time, of which 33 pharmaceutical companies have met the requirements, and 2 companies are not in production.
.
Among them, Guangxi Gehongtang Fanglue Pharmaceutical Co.
, Ltd.
, Guangxi Hongbo Pharmaceutical Co.
, Ltd.
, Guilin Rhine Pharmaceutical Co.
, Ltd.
, and Guangxi Zhongya Meiji Pharmaceutical Co.
, Ltd.
are in a state of suspension
.
On the whole, pharmaceutical companies have suspended production or ceased operations due to the existence of serious defects in the company, the company voluntarily applying for the cancellation of the certificate, and the failure to re-issue the certificate after the expiration of the validity period
.
Behind it, the medical environment is undergoing tremendous changes
.
With the advancement of national policies such as centralized procurement, the price reduction of drugs has become a major trend.
Many pharmaceutical companies are struggling to continue operating due to obvious pressure on profits.
Therefore, it is reasonable to choose to stop production and withdraw from the market
.
In this context, the industry predicts that with the intensified reshuffle of the pharmaceutical market in the future, companies that do not follow market rules and violate laws and regulations will face the outcome of being eliminated
.
But at the same time, the domestic pharmaceutical industry may also accelerate its development in the direction of high quality
.
, Ltd.
applied for the cancellation of the "Drug Production License" (No.
: Yunnan 20160153) to terminate the production of drugs
.
The cancellation of the application complies with the "Drug Administration Law of the People's Republic of China" (Order No.
31 of the President of the People's Republic of China) and other laws and regulations, and has been studied by the Yunnan Provincial Drug Administration and agreed to be cancelled
.
In fact, under the background of stricter industry supervision and fierce market competition, pharmaceutical companies that do not operate in a standardized way and are unable to operate are constantly withdrawing from the market in recent years
.
At present, judging from the fact that the provincial drug administrations have started to expose the inspection results of pharmaceutical companies in 2021, this trend is still accelerating.
In 2019, more than 10 pharmaceutical companies have been ordered to suspend production due to their own reasons or found illegal projects during the inspection of the Food and Drug Administration
.
For example, on December 31, the Hunan Provincial Food and Drug Administration issued an announcement stating that, according to the application of Huaihua Longyuan Pharmaceutical Co.
, Ltd.
Ethnic Chinese Herbal Pieces Factory and Zhijiang Dong Autonomous County Herbal Medicine Company Chinese Herbal Pieces Factory, the provincial bureau cancelled Huaihua Longyuan according to law.
The "Drug Production License" (No.
: Xiang 20160163), "Drug GMP Certificate" (Certificate No.
: HN20160194) of the Nationality Traditional Chinese Medicine Decoction Piece Factory of the Pharmaceutical Co.
, Ltd.
and the "Drug Production License" ( No.
: Xiang 20170207), "Drug GMP Certificate" (Certificate No.
: HN20170260)
.
On the same day, according to a production suspension notice issued by the Anhui Provincial Food and Drug Administration, Anhui Jucao Chinese Herbal Pieces Co.
, Ltd.
was found to have 1 serious defect (the drug quality management system could not operate effectively), and the Chinese medicine pieces had potential quality and safety hazards.
He was ordered by the Food and Drug Administration to suspend the production of Chinese herbal decoction pieces and filed a case for investigation
.
In addition, the Guangxi Zhuang Autonomous Region Food and Drug Administration also issued a notice on December 31 on the results of the special inspection on pharmacovigilance of drug manufacturers in 2021
.
The notice shows that a total of 39 pharmaceutical companies have been inspected this time, of which 33 pharmaceutical companies have met the requirements, and 2 companies are not in production.
.
Among them, Guangxi Gehongtang Fanglue Pharmaceutical Co.
, Ltd.
, Guangxi Hongbo Pharmaceutical Co.
, Ltd.
, Guilin Rhine Pharmaceutical Co.
, Ltd.
, and Guangxi Zhongya Meiji Pharmaceutical Co.
, Ltd.
are in a state of suspension
.
On the whole, pharmaceutical companies have suspended production or ceased operations due to the existence of serious defects in the company, the company voluntarily applying for the cancellation of the certificate, and the failure to re-issue the certificate after the expiration of the validity period
.
Behind it, the medical environment is undergoing tremendous changes
.
With the advancement of national policies such as centralized procurement, the price reduction of drugs has become a major trend.
Many pharmaceutical companies are struggling to continue operating due to obvious pressure on profits.
Therefore, it is reasonable to choose to stop production and withdraw from the market
.
In this context, the industry predicts that with the intensified reshuffle of the pharmaceutical market in the future, companies that do not follow market rules and violate laws and regulations will face the outcome of being eliminated
.
But at the same time, the domestic pharmaceutical industry may also accelerate its development in the direction of high quality
.
